- Home
- WVE vs HSII Comparison
WVE vs HSII Comparison
Compare WVE & HSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- HSII
- Stock Information
- Founded
- WVE 2012
- HSII 1953
- Country
- WVE Singapore
- HSII United States
- Employees
- WVE N/A
- HSII N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- HSII Diversified Commercial Services
- Sector
- WVE Health Care
- HSII Consumer Discretionary
- Exchange
- WVE Nasdaq
- HSII Nasdaq
- Market Cap
- WVE 915.6M
- HSII 1.0B
- IPO Year
- WVE 2015
- HSII 1999
- Fundamental
- Price
- WVE $7.35
- HSII $58.80
- Analyst Decision
- WVE Strong Buy
- HSII Buy
- Analyst Count
- WVE 14
- HSII 2
- Target Price
- WVE $20.50
- HSII $57.50
- AVG Volume (30 Days)
- WVE 3.6M
- HSII 332.9K
- Earning Date
- WVE 11-10-2025
- HSII 11-03-2025
- Dividend Yield
- WVE N/A
- HSII 1.02%
- EPS Growth
- WVE N/A
- HSII N/A
- EPS
- WVE N/A
- HSII 1.73
- Revenue
- WVE $109,230,000.00
- HSII $1,199,854,000.00
- Revenue This Year
- WVE N/A
- HSII $11.42
- Revenue Next Year
- WVE $6.24
- HSII $1.39
- P/E Ratio
- WVE N/A
- HSII $34.00
- Revenue Growth
- WVE 103.75
- HSII 11.56
- 52 Week Low
- WVE $5.28
- HSII $36.87
- 52 Week High
- WVE $16.38
- HSII $58.85
- Technical
- Relative Strength Index (RSI)
- WVE 49.41
- HSII 74.17
- Support Level
- WVE $6.60
- HSII $58.55
- Resistance Level
- WVE $7.27
- HSII $58.91
- Average True Range (ATR)
- WVE 0.53
- HSII 0.10
- MACD
- WVE -0.04
- HSII -0.21
- Stochastic Oscillator
- WVE 51.78
- HSII 72.22
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.